文献速递复苏、休克与脓毒症创伤与烧伤

冻干血浆减轻血红蛋白氧载体(HBOC-201)在失血与血液稀释复苏模型中的稀释效应

Freeze-dried plasma mitigates the dilution effects of a hemoglobin-based oxygen carrier (HBOC-201) in a model of resuscitation for hemorrhage and hemodilution.
PubMed 文献 · J Trauma Acute Care Surg · 2019-01-01
一句话结论体外研究表明,HBOC-201与冻干血浆按1:1联合用于容量替代可减轻HBOC单用所致的凝血指标恶化,作者认为相当于各1至2单位的剂量可考虑用于早期输血干预的临床研究。

该研究为体外实验室研究,通过用HBOC-201、冻干血浆或两者按原血量10%至50%比例替代全血(或预先用25% Plasmalyte A稀释的全血作为血液稀释模型)来模拟复苏。单用HBOC导致纤维蛋白原和细胞成分剂量依赖性下降,凝血酶原时间(PT)最高剂量时延长61%、活化部分凝血活酶时间(aPTT)延长40%,血栓弹力图(TEG)参数符合稀释性凝血病;单用冻干血浆虽相应降低细胞计数,但纤维蛋白原、PT、aPTT和TEG参数无统计学变化。HBOC与冻干血浆按1:1联合行容量替代时,上述HBOC单用的不良影响被减轻:最高剂量时PT和aPTT分别延长17%和11%;在预稀释样本中趋势相似且差异更明显。血小板在流动条件下对胶原的黏附直接受血细胞比容影响;含HBOC与组织型纤溶酶原激活剂的样本对纤溶高度敏感。

要点

  • 体外模型中单用HBOC-201行容量替代导致剂量依赖性纤维蛋白原与细胞成分下降,最高剂量时PT延长61%、aPTT延长40%,TEG符合稀释性凝血病。
  • 单用冻干血浆替代全血时细胞计数相应下降,但纤维蛋白原、PT、aPTT和TEG参数无统计学变化。
  • HBOC-201与冻干血浆按1:1联合替代时,最高剂量下PT和aPTT仅分别延长17%和11%,HBOC单用的不良影响被减轻。
  • 预稀释(25% Plasmalyte A)样本中上述趋势相似且差异更明显;血小板对胶原的黏附直接受血细胞比容影响。
  • 含HBOC与组织型纤溶酶原激活剂的样本对纤溶高度敏感,作者认为还需进一步研究HBOC对纤溶的影响。

适用人群与场景

  • 体外模拟失血与血液稀释复苏模型:全血或预先用25% Plasmalyte A稀释的全血。

处置流程与药物剂量

  • 以HBOC-201、冻干血浆或两者按原血量10%至50%的比例替代全血进行容量替代模拟。
  • HBOC-201与冻干血浆按1:1联合用于容量替代。
  • 在样本中加入组织型纤溶酶原激活剂以模拟失血性休克对纤溶的影响。

研究设计与关键结果

  • 体外实验室研究:单用HBOC替代全血导致纤维蛋白原和细胞成分剂量依赖性下降,最高剂量时PT延长61%、aPTT延长40%,TEG参数符合稀释性凝血病。
  • 单用冻干血浆替代全血时细胞计数相应下降,但纤维蛋白原、PT、aPTT和TEG参数无统计学变化。
  • HBOC与冻干血浆按1:1联合容量替代时,最高剂量下PT和aPTT分别延长17%和11%,HBOC单用的不良影响被减轻。
  • 预稀释样本中趋势相似且差异更明显;血小板对胶原的黏附直接受血细胞比容影响。
  • 含HBOC与组织型纤溶酶原激活剂的样本对纤溶高度敏感。

证据类型、等级与局限

  • 证据类型:体外实验室研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,相当于HBOC-201与冻干血浆各1至2单位的剂量对功能性凝血指标影响温和,作为早期输血干预的一部分可考虑用于临床研究。
  • 作者指出,更高剂量可能带来与晶体液或其他胶体复苏相似的血液稀释风险,尤其在凝血功能受损患者中。
  • 作者认为还需进一步研究HBOC对纤溶的影响。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Hemoglobin-based oxygen carriers (HBOCs) have proven useful for supplementing oxygen delivery when red cells are unavailable; however, HBOCs do not promote hemostasis. The need for prehospital bridges to blood transfusion informed this study which sought to determine the impact of HBOCs on coagulation, with or without cotransfusion of freeze-dried plasma (FDP).

METHODS: Treatment was simulated in vitro by replacing whole blood volume (or whole blood prediluted with 25% plasmalyte A as a hemodilution model) with HBOC-201, FDP, or both at ratios of 10% to 50% of original volume. Prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, complete blood count, viscosity, thromboelastography (TEG), and platelet adhesion to collagen under flow were evaluated. Subsequently, tissue plasminogen activator was added to model hemorrhagic shock effects on fibrinolysis.

RESULTS: Substituting blood with HBOC resulted in dose-dependent decreases in fibrinogen and cells, which lengthened PT (+61% at highest dose) and aPTT (+40% at highest dose) and produced TEG parameters consistent with dilutional coagulopathy. While substituting blood with FDP decreased cell counts accordingly, fibrinogen, PT, aPTT, and TEG parameters were not statistically changed. When HBOC and FDP were combined 1:1 for volume replacement, observed HBOC-only detriments were mitigated: PT and aPTT were increased by 17% and 11%, respectively, at the highest doses. In prediluted samples, similar trends were seen with exacerbated differences. Platelet adhesion to collagen was directly affected by hematocrit. Samples containing both HBOC and tissue plasminogen activator were highly susceptible to fibrinolysis.

CONCLUSION: A dose equivalent to 1 unit to 2 units each of HBOC-201 and FDP had a modest impact on functional coagulation measures and is reasonable to consider for clinical study as a part of early transfusion intervention. Higher doses may impart hemodilution risks similar to resuscitation with crystalloid or other colloids in coagulation-compromised patients. Further study of HBOC effects on fibrinolysis is also indicated.

STUDY TYPE: In vitro laboratory study.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Meledeo MA, Peltier GC, McIntosh CS, et al. Freeze-dried plasma mitigates the dilution effects of a hemoglobin-based oxygen carrier (HBOC-201) in a model of resuscitation for hemorrhage and hemodilution. J Trauma Acute Care Surg. 2019. PMID: 31246911. doi:10.1097/TA.0000000000002317

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。